Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442871 · ClinicalTrials.gov registry record · Phase 1
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00442871 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 29 participants.
The verdict
NCT00442871, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.
Interventions
- DRUG eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-09-28 |
| Est. Completion | 2008-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442871
The ClinicalTrials.gov registry entry for NCT00442871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eltrombopag is the first listed.
NCT00442871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442871 about?
NCT00442871 is a clinical study titled "Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment". The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus tho...
What is the current status of trial NCT00442871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-09-28. Estimated completion is 2008-01-03.
What interventions are being tested in trial NCT00442871?
The interventions under investigation include: eltrombopag (DRUG).
Who is sponsoring clinical trial NCT00442871?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.